Legend Biotech CEO Ying Huang shares a post-earnings update from the company's new R&D Center in Philadelphia
- Nov 13, 2025
- 1 min read
He describes how Legend is no longer capacity constrained for it's CAR-T treatment, Carvykti, and previews the upcoming ASH conference.














.png)

